FENNEC PHARMACEUTICALS INC. (FENC) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 27, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for FENNEC PHARMACEUTICALS INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, FENNEC PHARMACEUTICALS INC.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Continuing Negative
CHATGPT
Turned Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does FENNEC PHARMACEUTICALS INC. actually do?
Answer:
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity (CIO) in pediatric patients. Its sole FDA-approved product, PEDMARK (sodium thiosulfate injection), is the first and only therapy indicated to reduce the risk of hearing loss associated with cisplatin chemotherapy in pediatric patients aged one month and older with localized, non-metastatic solid tumors. PEDMARK has also received European Commission and UK approval under the brand name PEDMARQSI. The company has a licensing agreement with Norgine for commercialization in Europe, Australia, and New Zealand, and is pursuing partnerships in other international markets. Fennec operates with a virtual manufacturing model, relying on contract manufacturers for production.
Question:
What are FENNEC PHARMACEUTICALS INC.'s revenue drivers?
Answer:
Revenue is primarily driven by sales of PEDMARK in the United States and royalties and milestone payments from international licensing agreements, such as the one with Norgine.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required